ACS Clinical Research Program rss

figure 1

Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results(Comments Off)

October 1, 2015

The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.

Figure 1. ALCHEMIST schema

Biomarker-driven adjuvant targeted therapy for NSCLC—the ALCHEMIST trials

This month’s column summarizes the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) platform and how it facilities definitive studies of adjuvant targeted therapies in biomarker-selected non-small cell lung cancer patients.


PACES trial: Evaluating the effectiveness of eflornithine and sulindac in preventing colon adenomas

The S0820 Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) study seeks to determine whether two drugs that have shown early promise can significantly lower the risk of secondary colorectal polyp or cancer for these survivors.


Multimodality treatment considerations in esophageal and gastric cancer: Are we making progress?

This column addresses the efficacy of combining existing approaches with active therapeutic combinations to treat cancers of the stomach and esophagus.


New manual for cancer surgery issued: Operative Standards for Cancer Surgery

Operative Standards for Cancer Surgery, developed by the ACS Clinical Research Program Cancer Care Standards Development Committee, provides evidence-based guidelines for oncologic resections.

More in this category

« Older Posts   


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611